Fortress Biotech 9.375% Series A Preferred Stock
FBIOP
1 hedge funds and large institutions have $262K invested in Fortress Biotech 9.375% Series A Preferred Stock in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 1 → 1 (0)
1.09% less ownership
Funds ownership: 1.53% → 0.44% (-1.1%)
73% less capital invested
Capital invested by funds: $966K → $262K (-$704K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Shikiar Asset Management
New York
|
-$667K |
FBIOP Hedge Fund Activity: Q2 2023 in Review
1 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Fortress Biotech 9.375% Series A Preferred Stock (FBIOP) for Q2 2023, worth a combined $262K — down 73% from $966K a quarter earlier.
Fund positioning in FBIOP was balanced in Q2 2023: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was Shikiar Asset Management, cutting an estimated $667K.
- 1 institutional investor held Fortress Biotech 9.375% Series A Preferred Stock (FBIOP) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $262K of Fortress Biotech 9.375% Series A Preferred Stock stock for Q2 2023, down 73% quarter-over-quarter.
- 0 funds opened new Fortress Biotech 9.375% Series A Preferred Stock positions in Q2 2023 and 0 closed out.
- The largest Fortress Biotech 9.375% Series A Preferred Stock seller in Q2 2023 was Shikiar Asset Management, an estimated $667K sold.
Based on aggregated 13F filings for Q2 2023.